Technical platforms

Dr. Shakhawath Hossain is a researcher at the Department of Pharmacy at Uppsala University, specializing in Molecular Pharmaceutics. His expertise lies in computational pharmaceutics, particularly in the use of molecular dynamics simulations, in silico modeling, and machine learning to study drug delivery mechanisms and improve the bioavailability of poorly permeable molecules

Dr Ilse Dubbelboer is a researcher at Uppsala University's Department of Pharmaceutical Biosciences, where she works within the field of Translational Drug Discovery and Development. Her expertise includes pharmacokinetics, biopharmaceutics, and physiologically based modeling. She focuses on understanding drug absorption and distribution, particularly in relation to subcutaneous administration and drug transfer into milk during lactation. Her research also explores comparative and veterinary medicine, applying One Health principles to improve drug development across species and physiological conditions.

Dr. Tommaso Casalini is an Associate Principal Scientist at AstraZeneca in Gothenburg, with a background in chemical engineering and a strong focus on computational modeling for drug delivery. His work involves using molecular simulations—both atomistic and coarse-grained—to study the behavior of pharmaceutical formulations. He also develops mathematical models to understand drug release kinetics and the mechanical properties of biomaterials. By integrating computational techniques across multiple scales, he contributes to the design and optimization of advanced drug delivery systems.

Dr. Maria Karlgren is an Associate Professor at Uppsala University's Department of Pharmacy, with a specialization in molecular pharmaceutics. Her research focuses on drug absorption, distribution, metabolism, and excretion (ADME), particularly the role of transport proteins and metabolizing enzymes. She investigates how these factors influence drug permeability and interactions, aiming to improve predictions of drug behavior in the human body. Dr. Karlgren also contributes to the development of non-animal in vitro models, supporting ethical and effective drug testing strategies, especially in the context of drug delivery to the intestine.

Dr. Bertil Abrahamsson is a Senior Principal Scientist at AstraZeneca and Adjunct Professor in Biopharmaceutics at Uppsala University. He has over 25 years of experience in industrial drug development, primarily focused on oral biopharmaceutics and drug delivery. He has contributed significantly to the development of predictive models and formulation strategies that improve the performance and reliability of orally administered drugs. Through his work, he bridges academic research and industrial application, advancing translational approaches in pharmaceutical development.

Dr. Bengt Dahlström is a Senior Scientific Advisor at Clinical Trial Consultants (CTC). He has over 40 years of experience in pharmaceutical research and development, with a strong focus on clinical pharmacology and pharmacokinetics. His scientific competence includes the design and execution of early-phase clinical trials, optimization of drug dosing strategies, and the development of predictive models for drug absorption and metabolism. As a co-founder of several clinical research organizations—including CTC AB, PMC AB, and MiniDoc AB—he has played a key role in advancing translational research and bridging the gap between laboratory findings and clinical application.

Dr. Victor Agmo Hernández is a Senior Lecturer and Associate Professor at the Department of Medicinal Chemistry at Uppsala University, with a specialization in pharmaceutical physical chemistry. His scientific expertise centers on self-associated lipid systems, surface chemistry, and the interactions of lipid membranes and nanoparticles with biomolecules and pharmaceutical compounds. He applies advanced surface-sensitive techniques, including electrochemistry and nanogravimetry (QCM-D), to study the behavior of lipid-modified substrates and their interactions with peptides, proteins, drugs, and inorganic materials. His research contributes to the development of tailored interfaces and model systems for understanding drug delivery mechanisms at the molecular level.

Dr. Dan Lundberg

Prof. Göran Frenning is a Professor at the Department of Pharmaceutical Biosciences at Uppsala University, with deep expertise in pharmaceutical physics and computational modeling. His scientific focus lies in the mechanics of pharmaceutical powders, tablet compaction, and drug release modeling. He specializes in combining experimental techniques with theoretical and numerical methods, such as finite element analysis and discrete element modeling, to understand and predict the behavior of particulate systems during pharmaceutical processing. Professor Frenning’s research contributes significantly to the development of more efficient, predictable, and mechanistically informed drug delivery systems and manufacturing processes.

Dr. Madlen Hubert is an Associate Professor in Pharmaceutics at the Department of Pharmacy, Uppsala University. Her expertise lies at the intersection of drug delivery, biophysics, and molecular biology, with a strong focus on lipid-based nanoparticles and enabling formulations for the oral delivery of challenging therapeutics, including RNA-based drugs. She specializes in studying how nanoparticles interact with biological systems using advanced microscopy, cell-based assays, and biophysical techniques. A key part of her research involves developing clinically relevant in vitro models, particularly human intestinal organoids, to better predict drug behavior and improve formulation strategies.

Dr. Enrico Zambelli is a Sustainable Formulations Project Unit Manager at Chiesi Farmaceutici, with expertise in drug product development within the CMC (Chemistry, Manufacturing, and Controls) and R&D domains. His work focuses on the formulation and process development of pharmaceutical products, particularly in the context of pressurized metered dose inhalers (pMDIs) and other inhalation therapies. He has contributed to several patented inventions related to inhalation drug delivery systems, involving complex formulation strategies and propellant technologies. His background includes both technical and regulatory aspects of pharmaceutical development, and he has presented on topics such as drug process development, pharmaceutical industry organization, and experiential learning in formulation science